Author details

Full Name

Azra H Ligon

Affiliation

ORCID

Career Start Year

1995

Papers

113

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37683132	Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing.	JCO Oncol Pract	2024
36780194	ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma.	Clin Cancer Res	2023
36346171	Proliferating Pilar Tumors Are Characterized by Recurrent 15q, 6q, and 6p22.2 Alterations.	American Journal of Dermatopathology	2023
34508644	A molecularly integrated grade for meningioma.	Neuro Oncol	2022
36176068	Chromosomal microarray analysis in pregnancy loss: Is it time for a consensus approach?	Prenatal Diagnosis	2022
35307742	Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.	Neuro Oncol	2022
33414136	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.	Clin Cancer Res	2021
33631016	A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.	Neuro Oncol	2021
32871584	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.	Blood	2021
33077919	Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.	Modern Pathology	2021
31375768	Characterization of molecular signatures of supratentorial ependymomas.	Mod Pathol	2020
32203924	Copy number assessment in the genomic analysis of CNS neoplasia: An evidence-based review from the cancer genomics consortium (CGC) working group on primary CNS tumors.	Cancer Genet	2020
32322066	Mechanisms and therapeutic implications of hypermutation in gliomas.	Nature	2020
32141887	A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.	Am J Surg Pathol	2020
32665022	Molecular and clinicopathologic features of gliomas harboring NTRK fusions.	Acta Neuropathol Commun	2020
31151904	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.	Lancet Oncol	2019
31609651	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.	Journal of Clinical Oncology	2019
30620669	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.	Journal of Clinical Oncology	2019
31115453	Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.	Am J Clin Pathol	2019
31355086	Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma.	Cureus	2019
31112476	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.	Journal of Clinical Oncology	2019
29758594	PHOX2B is a reliable immunomarker in distinguishing peripheral neuroblastic tumours from CNS embryonal tumours.	Histopathology	2018
29394125	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.	Journal of Clinical Oncology	2018
28104717	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.	Neuro Oncol	2017
28557599	Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.		2017
28339723	Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.	Neuro Oncol	2017
27707790	Landscape of Genomic Alterations in Pituitary Adenomas.	Clin Cancer Res	2017
28170043	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.	Neuro Oncol	2017
27879515	Atypical Spindle Cell Lipomatous Tumor: Clinicopathologic Characterization of 232 Cases Demonstrating a Morphologic Spectrum.	American Journal of Surgical Pathology	2017
27737878	Classical Hodgkin Lymphoma with Reduced Î²2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.	Cancer Immunology Research	2016
27425854	Genomic characterization of recurrent high-grade astroblastoma.	Cancer Genet	2016
26913631	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.	JAMA Oncology	2016
26829751	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism.	Nat Genet	2016
27270588	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.	Nat Med	2016
26826201	Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.	Neuro Oncol	2016
27269947	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.	Journal of Clinical Oncology	2016
27037490	Reporting of Diagnostic Cytogenetic Results.	Curr Protoc Hum Genet	2016
26817999	Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma.	Diagn Pathol	2016
27451390	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.	Lancet Oncology, The	2016
27069084	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.	Journal of Clinical Oncology	2016
26482041	Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.	Clinical Cancer Research	2016
26226092	Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation.	World Neurosurg	2016
26702065	Targetable genetic features of primary testicular and primary central nervous system lymphomas.	Blood	2016
26323607	A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.	Neuro Oncol	2016
27882345	Institutional implementation of clinical tumor profiling on an unselected cancer population.	JCI Insight	2016
25963524	ARID1A and TERT promoter mutations in dedifferentiated meningioma.	Cancer Genet	2015
25754088	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.	Neuro Oncol	2015
25825052	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.	Neuro Oncol	2015
25482239	PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.	New England Journal of Medicine	2015
24705250	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.	Nat Genet	2014